The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Minghui ^a   Dong, Yuandi ^a   Liu, Haitao ^a   Wang, Yan ^b   Zhao, Shu ^a   Xuan, Qijia ^a   Zhang, Qingyuan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG PROVINCIAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

HUMAN; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; ODDS RATIO; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; SURVIVAL ANALYSIS;

B7-H1 ANTIGEN; BIOMARKERS, TUMOR; HUMANS; LYMPHATIC METASTASIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 85000836785     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37933     Document Type: Article

References (33)

1. Siegel, R. L., Miller, K. D., & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7-30 (2016).
2. Ajani, J. A. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 6, 813-814 (2008).
3. Dittmar, Y., & Settmacher, U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World J Gastrointest Oncol 7, 292-302 (2015).
4. Zou, W., Wolchok, J. D., & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8, 328rv324 (2016).
5. Hansen, J. D., et al. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol Immunol 46, 457-472 (2009).
6. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264 (2012).
7. Sanmamed, M. F., & Chen, L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 20, 256-261 (2014).
8. Francisco L. M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206, 3015-3029 (2009).
9. Wu, P., Wu, D., Li, L., Chai, Y., & Huang, J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One 10, e0131403 (2015).
10. Chowdhury, S., et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget (2016).
11. Cierna, Z., et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol 27, 300-305 (2016).
12. Katsuya, Y., et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 88, 154-159 (2015).
13. Zheng, P., & Zhou, Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer 7, 15-18 (2015).
14. Ioannidis, J. P., & Trikalinos, T. A. The appropriateness of asymmetry tests for publication bias in meta-Analyses: a large survey. Cmaj 176, 1091-1096 (2007).
15. Jin, Y., Zhao, J., Shi, X., & Yu, X. Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-Analysis. J Cancer Res Ther 11 Suppl 1, C38-43 (2015).
16. Wu, C., et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108, 19-24 (2006).
17. Geng, Y., et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol 20, 273-281 (2015).
18. Hou, J., et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 96, 284-291 (2014).
19. Qing, Y., et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 9, 901-909 (2015).
20. Tamura, T., et al. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. Anticancer Res 35, 5369-5376 (2015).
21. Wang, L. A., Wei, X., Li, Q., & Chen, L. The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography. Tumour Biol (2015).
22. Zhang, L., et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol 8, 11084-11091 (2015).
23. Eto, S., et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer 19, 466-471 (2016).
24. Kim, J. W., et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19, 42-52 (2016).
25. Christine, B., et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget (2016).
26. Huang, B., et al. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-Analysis. Onco Targets Ther 8, 2617-2625 (2015).
27. Liu, Y. X., et al. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-Analysis. Onco Targets Ther 9, 2649-2654 (2016).
28. Sun, J., et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-Associated PD-L1 signaling by two functional monoclonal antibodies. Tissue antigens 69, 19-27 (2007).
29. Zou, W., & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8, 467-477 (2008).
30. Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 41, 868-876 (2015).
31. Xu, F., et al. Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 94, e1911 (2015).
32. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25, 603-605 (2010).
33. Parmar, M. K., Torri, V., & Stewart, L. Extracting summary statistics to perform meta-Analyses of the published literature for survival endpoints. Stat Med 17, 2815-2834 (1998).